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277I N T RODUC T I ON
Myocardial infarction (MI) can be recognised by
clinical features, including electrocardiographic
(ECG) ﬁndings, elevated values of biochemical
markers (biomarkers) of myocardial necrosis, and
by imaging, or may be deﬁned by pathology. It is
a major cause of death and disability worldwide.
MI may be the ﬁrst manifestation of coronary artery
disease (CAD) or it may occur, repeatedly, in
patients with established disease. Information on
MI rates can provide useful information regarding
the burden of CAD within and across populations,
especially if standardized data are collected in
a manner that distinguishes between incident and
recurrent events. From the epidemiological point
of view, the incidence of MI in a population can
be used as a proxy for the prevalence of CAD in
that population. The term ‘myocardial infarction’
may have major psychological and legal implications
for the individual and society. It is an indicator of
one of the leading health problems in the world
and it is an outcome measure in clinical trials, obser-
vational studies and quality assurance programmes.
These studies and programmes require a precise
and consistent deﬁnition of MI.
In the past, a general consensus existed for the
clinical syndrome designated as MI. In studies of
disease prevalence, the World Health Organization
(WHO) deﬁned MI from symptoms, ECG abnor-
malities and cardiac enzymes. However, the devel-
opment of ever more sensitive and myocardial
tissue-speciﬁc cardiac biomarkers and more sensitive
imaging techniques now allows for detection of very
small amounts of myocardial injury ornecrosis.
Additionally, the management of patients with MI
has signiﬁcantly improved, resulting in less myocar-
dial injury and necrosis, in spite of a similar clinical
presentation. Moreover, it appears necessary to
distinguish the various conditions which may cause
MI, such as ‘spontaneous’ and ‘procedure-related’
MI. Accordingly, physicians, other healthcare
providers and patients require an up-to-date deﬁni-
tion of MI.
In 2000, the First Global MI Task Force pre-
sented a new deﬁnition of MI, which implied
that any necrosis in the setting of myocardial
ischaemia should be labelled as MI [1]. These
principles were further reﬁned by the Second
Global MI Task Force, leading to the Universal
Deﬁnition of Myocardial Infarction Consensus
Document in 2007, which emphasized the
different conditions which might lead to an MI[2]. This document, endorsed by the European
Society of Cardiology (ESC), the American
College of Cardiology Foundation (ACCF), the
American Heart Association (AHA), and the
World Heart Federation (WHF), has been well
accepted by the medical community and adopted
by the WHO [3]. However, the development of
even more sensitive assays for markers of myocar-
dial necrosis mandates further revision, particularly
when such necrosis occurs in the setting of the crit-
ically ill, after percutaneous coronary procedures or
after cardiac surgery. The Third Global MI Task
Force has continued the Joint ESC/ACCF/
AHA/WHF efforts by integrating these insights
and new data into the current document, which
now recognizes that very small amounts of myocar-
dial injury or necrosis can be detected by biochem-
ical markers and/or imaging.
PA THO LOG I C A L CHARAC T E R I S T I C S O F
MYOCARD I A L I S CHA EM I A AND
I N FA R C T I ON
MI is deﬁned in pathology as myocardial cell death
due to prolonged ischaemia. After the onset of
myocardial ischaemia, histological cell death is not
immediate, but takes a ﬁnite period of time to
developdas little as 20 min, or less in some animal
models [4]. It takes several hours before myocardial
necrosis can be identiﬁed by macroscopic or micro-
scopic post-mortem examination. Complete
necrosis of myocardial cells at risk requires at least
2e4 h, or longer, depending on the presence of
collateral circulation to the ischaemic zone, persis-
tent or intermittent coronary arterial occlusion, the
sensitivity of the myocytes to ischaemia, precondi-
tioning, and individual demand for oxygen and
nutrients [2]. The entire process leading to a healed
infarction usually takes at least 5e6 weeks. Reperfu-
sion may alter the macroscopic and microscopic
appearance.
B I OMARK E R D E T E C T I ON OF
MYOCARD I A L I N J U R Y W I TH N E C RO S I S
Myocardial injury is detected when blood levels of
sensitive and speciﬁc biomarkers such as cTn or the
MB fraction of creatine kinase (CKMB) are
increased [2]. Cardiac troponin I and T are
components of the contractile apparatus of
myocardial cells and are expressed almost exclu-
sively in the heart. Although elevations of these
biomarkers in the blood reﬂect injury leading to
Deﬁnition of myocardial infarction
Criteria for acute myocardial infarction
The term acute myocardial infarction (MI) should be used when there is evidence of myocardial necrosis in a clin-
ical setting consistent with acute myocardial ischaemia. Under these conditions any one of the following criteria
meets the diagnosis for MI:
d Detection of a rise and/or fall of cardiac biomarker values [preferably cardiac troponin (cTn)] with at least one
value above the 99th percentile upper reference limit (URL) and with at least one of the following:
d Symptoms of ischaemia.
d New or presumed new signiﬁcant ST-segmenteT wave (STeT) changes or new left bundle branch block
(LBBB).
d Development of pathological Q waves in the ECG.
d Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
d Identiﬁcation of an intracoronary thrombus by angiography or autopsy.
d Cardiac death with symptoms suggestive of myocardial ischaemia and presumed new ischaemic ECG changes or
new LBBB,but death occurred before cardiac biomarkers were obtained, or before cardiac biomarker values
would be increased.
d Percutaneous coronary intervention (PCI) related MI is arbitrarily deﬁned by elevation of cTn values (>5  99th
percentile URL) in patients with normal baseline values (99th percentile URL) or a rise of cTn values >20% if
the baseline values are elevated and are stable or falling. In addition, either (i) symptoms suggestive of myocardial
ischaemia or (ii) new ischaemicECGchanges or (iii) angiographicﬁndings consistent with a procedural complication
or (iv) imagingdemonstration of new loss of viablemyocardiumornew regionalwallmotion abnormality are required.
d Stent thrombosis associated with MI when detected by coronary angiography or autopsy in the setting of
myocardial ischaemia and with a rise and/or fall of cardiac biomarker values with at least one value above the
99th percentile URL.
d Coronary artery bypass grafting (CABG) related MI is arbitrarily deﬁned by elevation of cardiac biomarker
values (>10 x 99th percentile URL) in patients with normal baseline cTn values (99th percentile URL). In
addition, either (i) new pathological Q waves or new LBBB, or (ii) angiographic documented new graft or
new native coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or new regional
wall motion abnormality.
Criteria for prior myocardial infarction
Any one of the following criteria meets the diagnosis for prior MI:
d Pathological Q waves with or without symptoms in the absence of non-ischaemic causes.
d Imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of
a non-ischaemic cause.
d Pathological ﬁndings of a prior MI.
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278necrosis of myocardial cells, they do not indicate
the underlying mechanism [5]. Various possibili-
ties have been suggested for release of structural
proteins from the myocardium, including normal
turnover of myocardial cells, apoptosis, cellular
release of troponin degradation products, increased
cellular wall permeability, formation and release of
membranous blebs, and myocyte necrosis [6].
Regardless of the pathobiology, myocardial
necrosis due to myocardial ischaemia is designated
as MI.
Also, histological evidence of myocardial injury
with necrosis may be detectable in clinical condi-
tions associated with predominantly non-ischaemicmyocardial injury. Small amounts of myocardial
injury with necrosis may be detected, which are
associated with heart failure (HF), renal failure,
myocarditis, arrhythmias, pulmonary embolism or
otherwise uneventful percutaneous or surgical coro-
nary procedures. These should not be labelled as MI
or a complication of the procedures, but rather as
myocardial injury, as illustrated in Figure 1. It is
recognized that the complexity of clinical circum-
stances may sometimes render it difﬁcult to deter-
mine where individual cases may lie within the
ovals of Figure 1. In this setting, it is important to
distinguish acute causes of cTn elevation, which
require a rise and/or fall of cTn values, from chronic
Figure 1. This illustration shows various clinical entities: for example, renal failure, heart failure, tachy- or bradyarrhythmia, cardiac
or non- cardiac procedures that can be associated with myocardial injury with cell death marked by cardiac troponin elevation.
However, these entities can also be associated with myocardial infarction in case of clinical evidence of acute myocardial ischaemia
with rise and/or fall of cardiac troponin.
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279elevations that tend not to change acutely. A list of
such clinical circumstances associated with elevated
values of cTn is presented in Table 1. The multifac-
torial contributions resulting in the myocardial
injury should be described in the patient record.
The preferred biomarkerdoverall and for each
speciﬁc category of MIdis cTn (I or T), which has
highmyocardial tissue speciﬁcity aswell as high clinical
sensitivity. Detection of a rise and/or fall of the
measurements is essential to the diagnosis of acute
MI [7]. An increased cTn concentration is deﬁned
as a value exceeding the 99th percentile of a normal
reference population [upper reference limit (URL)].
This discriminatory 99th percentile is designated as
the decision level for the diagnosis of MI and must
be determined for each speciﬁc assay with appropriate
quality control in each laboratory [8,9]. The values for
the 99th percentile URL deﬁned by manufacturers,
including those for many of the high-sensitivity assays
in development, can be found in the package inserts for
the assays or in recent publications [10,11,12].
Values should be presented as nanograms per
litre (ng/L) or picograms per millilitre (pg/mL) to
make whole numbers. Criteria for the rise of cTn
values are assay-dependent but can be deﬁned
from the precision proﬁle of each individual assay,
including high-sensitivity assays [10,11]. Optimal
precision, as described by coefﬁcient of variation(CV) at the 99th percentile URL for each assay,
should be deﬁned as 10%. Better precision (CV
10%) allows for more sensitive assays and facili-
tates the detection of changing values [13]. The
use of assays that do not have optimal precision
(CV >10% at the 99th percentile URL) makes
determination of a signiﬁcant change more difﬁcult
but does not cause false positive results. Assays with
CV >20% at the 99th percentile URL should not be
used [13]. It is acknowledged that pre-analytic and
analytic problems can induce elevated and reduced
values of cTn [10,11].
Blood samples for the measurement of cTn
should be drawn on ﬁrst assessment and repeated
3e6 h later. Later samples are required if further
ischaemic episodes occur, or when the timing of
the initial symptoms is unclear [14]. To establish
the diagnosis of MI, a rise and/or fall in values
with at least one value above the decision level is
required, coupled with a strong pre-test likelihood.
The demonstration of a rising and/or falling pattern
is needed to distinguish acute- from chronic eleva-
tions in cTn concentrations that are associated
with structural heart disease [10,11,15e19]. For
example, patients with renal failure or HF can
have signiﬁcant chronic elevations in cTn. These
elevations can be marked, as seen in many patients
with MI, but do not change acutely [7]. However,
Table 1. Elevations of cardiac troponin values because of
myocardial injury
Injury related to primary myocardial ischaemia
Plaque rupture
Intraluminal coronary artery thrombus formation
Injury related to supply/demand imbalance of myocardial
ischaemia
Tachy-/brady-arrhythmias
Aortic dissection or severe aortic valve disease
Hypertrophic cardiomyopathy
Cardiogenic, hypovolaemic, or septic shock
Severe respiratory failure
Severe anaemia
Hypertension with or without LVH
Coronary spasm
Coronary embolism or vasculitis
Coronary endothelial dysfunction without signiﬁcant CAD
Injury not related to myocardial ischaemia
Cardiac contusion, surgery, ablation, pacing, or deﬁbrillator
shocks
Rhabdomyolysis with cardiac involvement
Myocarditis
Cardiotoxic agents, e.g. anthracyclines, herceptin
Multifactorial or indeterminate myocardial injury
Heart failure
Stress (Takotsubo) cardiomyopathy
Severe pulmonary embolism or pulmonary hypertension
Sepsis and critically ill patients
Renal failure
Severe acute neurological diseases, e.g. stroke, subarachnoid
haemorrhage
Inﬁltrative diseases, e.g. amyloidosis, sarcoidosis
Strenuous exercise
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280a rising or falling pattern is not absolutely necessary
to make the diagnosis of MI if a patient with a high
pre-test risk of MI presents late after symptom
onset; for example, near the peak of the cTn time-
concentration curve or on the slow-declining
portion of that curve, when detecting a changing
pattern can be problematic. Values may remain
elevated for 2 weeks or more following the onset
of myocyte necrosis [10].
Sex-dependent values may be recommended for
high-sensitivity troponin assays [20,21]. An
elevated cTn value (>99th percentile URL), with
or without a dynamic pattern of values or in the
absence of clinical evidence of ischaemia, should
prompt a search for other diagnoses associated
with myocardial injury, such as myocarditis, aortic
dissection, pulmonary embolism, or HF. Renal
failure and other more non-ischaemic chronic
disease states, that can be associated with elevated
cTn levels, are listed in Table 1 [10,11].If a cTn assay is not available, the best alternative
is CKMB (measured by mass assay). As with
troponin, an increased CKMB value is deﬁned as
a measurement above the 99th percentile URL,
which is designated as the decision level for the
diagnosis of MI [22]. Sex-speciﬁc values should
be employed [22].
C L I N I C A L F E A TUR E S O F MYOCA RD I A L
I S CHA EM I A AND I N FAR C T I ON
Onset of myocardial ischaemia is the initial step in
the development of MI and results from an imbal-
ance between oxygen supply and demand. Myocar-
dial ischaemia in a clinical setting can usually be
identiﬁed from the patient’s history and from
the ECG. Possible ischaemic symptoms include
various combinations of chest, upper extremity,
mandibular or epigastric discomfort (with exertion
or at rest) or an ischaemic equivalent such as dysp-
noea or fatigue. The discomfort associated with
acute MI usually lasts >20 min. Often, the discom-
fort is diffusednot localized, nor positional, nor
affected by movement of the regiondand it may
be accompanied by diaphoresis, nausea or syncope.
However, these symptoms are not speciﬁc for
myocardial ischaemia. Accordingly, they may be
misdiagnosed and attributed to gastrointestinal,
neurological, pulmonary or musculoskeletal disor-
ders. MI may occur with atypical symptomsdsuch
as palpitations or cardiac arrestdor even without
symptoms; for example in women, the elderly, dia-
betics, or post-operative and critically ill patients
[2]. Careful evaluation of these patients is advised,
especially when there is a rising and/or falling
pattern of cardiac biomarkers.
C L I N I C A L C L A S S I F I C A T I ON OF
MYOCARD I A L I N FA R C T I ON
For the sake of immediate treatment strategies, such
as reperfusion therapy, it is usual practice to desig-
nate MI in patients with chest discomfort, or other
ischaemic symptoms that develop ST elevation in
two contiguous leads (see ECG section), as an
‘ST elevation MI’ (STEMI). In contrast, patients
without ST elevation at presentation are usually
designated as having a ‘non-ST elevation MI’
(NSTEMI). Many patients with MI develop Q
waves (Q wave MI), but others do not (non-Q
MI). Patients without elevated biomarker values
can be diagnosed as having unstable angina. In
addition to these categories, MI is classiﬁed into
Table 2. Universal classiﬁcation of myocardial infarction
Type 1: Spontaneous myocardial infarction
Spontaneous myocardial infarction related to atherosclerotic plaque rupture, ulceration, ﬁssuring, erosion, or dissection with resulting
intraluminal thrombus in one or more of the coronary arteries leading to decreased myocardial blood ﬂow or distal platelet emboli with
ensuing myocyte necrosis. The patient may have underlying severe CAD but on occasion non-obstructive or no CAD.
Type 2: Myocardial infarction secondary to an ischaemic imbalance
In instances of myocardial injury with necrosis where a condition other than CAD contributes to an imbalance between myocardial oxygen
supply and/or demand, e.g. coronary endothelial dysfunction, coronary artery spasm, coronary embolism, tachy-/brady-arrhythmias,
anaemia, respiratory failure, hypotension, and hypertension with or without LVH.
Type 3: Myocardial infarction resulting in death when biomarker values are unavailable
Cardiac death with symptoms suggestive of myocardial ischaemia and presumed new ischaemic ECG changes or new LBBB, but death
occurring before blood samples could be obtained, before cardiac biomarker could rise, or in rare cases cardiac biomarkers were not
collected.
Type 4a: Myocardial infarction related to percutaneous coronary intervention (PCI)
Myocardial infarction associated with PCI is arbitrarily deﬁned by elevation of cTn values >5 x 99th percentile URL in patients with normal
baseline values (99th percentile URL) or a rise of cTn values >20% if the baseline values are elevated and are stable or falling. In addi-
tion,either (i) symptoms suggestive of myocardial ischaemia, or (ii) new ischaemic ECG changes or new LBBB, or (iii) angiographic loss of
patency of a major coronary artery or a side branch or persistent slow- or no-ﬂow or embolization, or (iv) imaging demonstration of new loss
of viable myocardium or new regional wall motion abnormality are required.
Type 4b: Myocardial infarction related to stent thrombosis
Myocardial infarction associated with stent thrombosis is detected by coronary angiography or autopsy in the setting of myocardial
ischaemia and with a rise and/or fall of cardiac biomarkers values with at least one value above the 99th percentile URL.
Type 5: Myocardial infarction related to coronary artery bypass grafting (CABG)
Myocardial infarction associated with CABG is arbitrarily deﬁned by elevation of cardiac biomarker values >10 x 99th percentile URL in
patients with normal baseline cTn values (99th percentile URL). In addition, either (i) new pathological Q waves or new LBBB, or (ii)
angiographic documented new graft or new native coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or
new regional wall motion abnormality.
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281various types, based on pathological, clinical and
prognostic differences, along with different treat-
ment strategies (Table 2).
Spontaneous myocardial infarction (MI type
1). This is an event related to atherosclerotic plaque
rupture, ulceration, ﬁssuring, erosion, or dissection
with resulting intralum-inal thrombus in one or
more of the coronary arteries, leading to decreased
myocardial blood ﬂow or distal platelet emboli
with ensuing myocyte necrosis. The patient may
have underlying severe CAD but, on occasion (5
to 20%), non-obstructive or no CAD may be found
at angiography, particularly in women [2325].
Myocardial infarction secondary to an ischaemic
imbalance (MI type 2). In instances of myocardial
injury with necrosis, where a condition other than
CAD contributes to an imbalance between myocar-
dial oxygen supply and/or demand, the term ‘MI
type 2’ is employed (Figure 2). In critically ill
patients, or in patients undergoing major (non-
cardiac) surgery, elevated values of cardiac biomarkers
may appear, due to the direct toxic effects of endog-
enous or exogenous high circulating catecholamine
levels. Also coronary vasospasm and/or endothelial
dysfunction have the potential to cause MI [2628].Cardiac death due to myocardial infarction (MI
type 3). Patients who suffer cardiac death, with
symptoms suggestive of myocardial ischaemia
accompanied by presumed new ischaemic ECG
changes or new LBBBdbut without available
biomarker valuesd represent a challenging diag-
nostic group. These individuals may die before
blood samples for biomarkers can be obtained, or
before elevated cardiac biomarkers can be identiﬁed.
If patients present with clinical features of myocar-
dial ischaemia, or with presumed new ischaemic
ECG changes, they should be classiﬁed as having
had a fatal MI, even if cardiac biomarker evidence
of MI is lacking.
Myocardial infarction associated with revasculari-
zation procedures (MI types 4 and 5). Periproce-
dural myocardial injury or infarction may occur at
some stages in the instrumentation of the heart
that is required during mechanical revascularization
procedures, either by PCI or by coronary artery
bypass grafting (CABG). Elevated cTn values may
be detected following these procedures, since
various insults may occur that can lead to myocardial
injury with necrosis [2932]. It is likely that limita-
tion of such injury is beneﬁcial to the patient:
Figure 2. Differentation between myocardial infarction (MI) types 1 and 2 according to the condition of the coronary arteries.
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282however, a threshold for a worsening prognosis,
related to an asymptomatic increase of cardiac
biomarker values in the absence of procedural
complications, is not well deﬁned [3335]. Subcat-
egories of PCI-related MI are connected to stent
thrombosis and restenosis that may happen after
the primary procedure.
E L E C T ROCARD I OGRAPH I C D E T E C T I ON
OF MYOCARD I A L I N F A R C T I ON
The ECG is an integral part of the diagnostic work-
up of patients with suspected MI and should be
acquired and interpreted promptly (i.e. target within
10 min) after clinical presentation [2]. Dynamic
changes in the ECG waveforms during acute
myocardial ischaemic episodes often require acquisi-
tion of multiple ECGs, particularly if the ECG at
initial presentation is non-diagnostic. Serial record-
ings in symptomatic patients with an initial non-
diagnostic ECG should be performed at 15-30
min intervals or, if available, continuous
computer-assisted 12-lead ECG recording. Recur-
rence of symptoms after an asymptomatic interval
are an indication for a repeat tracing and, in patients
with evolving ECG abnormalities, a pre-discharge
ECG should be acquired as a baseline for future
comparison. Acute or evolving changes in the
STeT waveforms and Q waves, when present,
potentially allow the clinician to time the event, to
identify the infarct-related artery, to estimate the
amount of myocardium at risk as well as prognosis,
and to determine therapeutic strategy. More
profound ST-segment shift or T wave inversioninvolving multiple leads/territories is associated
with a greater degree of myocardial ischae- mia
and a worse prognosis. Other ECG signs associated
with acute myocardial ischaemia include cardiac
arrhythmias, intraventricular and atrioventricular
conduction delays, and loss of precordial R wave
amplitude. Coronary artery size and distribution of
arterial segments, collateral vessels, location, extent
and severity of coronary stenosis, and prior myocar-
dial necrosis can all impact ECG manifestations of
myocardial ischaemia [36]. Therefore the ECG at
presentation should always be compared to prior
ECG tracings, when available. The ECG by itself
is often insufﬁcient to diagnose acute myocardial
ischaemia or infarction, since ST deviation may be
observed in other conditions, such as acute pericar-
ditis, left ventricular hypertrophy (LVH), left
bundle branch block (LBBB), Brugada syndrome,
stress cardiomyopathy, and early repolarization
patterns [37]. Prolonged new ST-segment elevation
(e.g. >20 min), particularly when associated with
reciprocal ST-segment depression, usually reﬂects
acute coronary occlusion and results in myocardial
injury with necrosis. As in cardiomyopathy, Q
waves may also occur due to myocardial ﬁbrosis in
the absence of CAD.
ECG abnormalities of myocardial ischaemia or
infarction may be inscribed in the PR segment,
the QRS complex, the ST-segment or the T
wave. The earliest manifestations of myocardial
ischaemia are typically T wave and ST-segment
changes. Increased hyperacute T wave amplitude,
with prominent symmetrical T waves in at least
two contiguous leads, is an early sign that may
G L O B A L H E A R T , V O L . 7 , N O . 4 , 2 0 1 2 Thygesen et al.
D e c e m b e r 2 0 1 2 : 2 7 5 – 2 9 5
Third Universal Deﬁnition of Myocardial Infarction
283precede the elevation of the ST-segment. Transient
Q waves may be observed during an episode of acute
ischaemia or (rarely) during acute MI with success-
ful reperfusion. Table 3 lists STeT wave criteria for
the diagnosis of acute myocardial ischaemia that
may or may not lead to MI. The J point is used
to determine the magnitude of the ST-segment
shift. New, or presumed new, J point elevation
0.1mV is required in all leads other than V2 and
V3. In healthy men under age 40, J-point elevation
can be as much as 0.25 mV in leads V2 or V3, but it
decreases with increasing age. Sex differences
require different cut-points for women, since J point
elevation in healthy women in leads V2 and V3 is
less than in men [38]. ‘Contiguous leads’ refers to
lead groups such as anterior leads (V1V6), inferior
leads (II, III, aVF) or lateral/apical leads (I, aVL).
Supplemental leads such as V3R and V4R reﬂect
the free wall of the right ventricle and V7V9 the
infero-basal wall.
The criteria in Table 3 require that the ST shift
be present in two or more contiguous leads. For
example, 0.2 mV of ST elevation in lead V2,
and 0.1 mV in lead V1, would meet the criteria
of two abnormal contiguous leads in a man >40
years old. However, 0.1mV and <0.2mV of ST
elevation, seen only in leads V2-V3 in men (or
<0.15mV in women), may represent a normal
ﬁnding. It should be noted that, occasionally, acute
myocardial ischaemia may create sufﬁcient ST-
segment shift to meet the criteria in one lead but
have slightly less than the required ST shift in
a contiguous lead. Lesser degrees of ST displacement
or T wave inversion do not exclude acute myocardial
ischaemia or evolving MI, since a single static
recording may miss the more dynamic ECG changes
that might be detected with serial recordings. ST
elevation or diagnostic Q waves in contiguous lead
groups are more speciﬁc than ST depression in local-
izing the site of myocardial ischaemia or necrosis
[39,40]. Supplemental leads, as well as serial ECGTable 3. ECG manifestations of acute myocardial ischaemia (in
absence of LVH and LBBB)
ST elevation
New ST elevation at the J point in two contiguous leads with
the cut-points: 0.1 mV in all leads other than leads V2V3
where the following cut points apply: 0.2 mV in men 40
years; 0.25 mV in men <40 years, or 0.15 mV in women.
ST depression and T wave changes
New horizontal or down-sloping ST depression 0.05 mV in
two contiguous leads and/or T inversion 0.1 mV in two
contiguous leads with prominent R wave or R/S ratio >1.recordings, should always be considered in patients
that present with ischaemic chest pain and a non-
diagnostic initial ECG [41,42].
Electrocardiographic evidence of myocardial
ischaemia in the distribution of a left circumﬂex
artery is often overlooked and is best captured using
posterior leads at the ﬁfth intercostal space (V7 at the
left posterior axillary line, V8 at the left mid-scapular
line, and V9 at the left paraspinal border). Recording
of these leads is strongly recommended in patients
with high clinical suspicion for acute circumﬂex
occlusion (for example, initial ECG nondiagnostic,
or ST-segment depression in leads V13) [41]. A
cut-point of 0.05 mV ST elevation is recommended
in leads V7-V9; speciﬁcity is increased at a cut-point
0.1 mV ST elevation and this cut- point should
be used in men <40 years old. ST depression in leads
V1-V3 may be suggestive of infero-basal myocardial
ischaemia (posterior infarction), especially when the
terminal T wave is positive (ST elevation equivalent),
however this is non-speciﬁc [4143]. In patients
with inferior and suspected right ventricular infarc-
tion, right pre-cordial leads V3R and V4R should be
recorded, since ST elevation 0.05 mV (0.1 mV
in men <30 years old) provides supportive criteria
for the diagnosis [42].
During an episode of acute chest discomfort,
pseudo- normalization of previously inverted T
waves may indicate acute myocardial ischaemia.
Pulmonary embolism, intracranial processes, elec-
trolyte abnormalities, hypothermia, or peri-/myo-
carditis may also result in STeT abnormalities and
should be considered in the differential diagnosis.
The diagnosis of MI is more difﬁcult in the presence
of LBBB [44,45]. However, concordant ST-
segment elevation or a previous ECGmay be helpful
to determine the presence of acute MI in this
setting. In patients with right bundle branch block
(RBBB), STeT abnormalities in leads V1V3 are
common, making it difﬁcult to assess the presence
of ischaemia in these leads: however, when new
ST elevation or Q waves are found, myocardial
ischaemia or infarction should be considered.
P R I O R MYOCARD I A L I N F A R C T I ON
As shown in Table 4, Q waves or QS complexes in
the absence of QRS confounders are pathogno-
monic of a prior MI in patients with ischaemic heart
disease, regardless of symptoms [46,47]. The speci-
ﬁcity of the ECG diagnosis for MI is greatest when
Q waves occur in several leads or lead groupings.
When the Q waves are associated with ST
Table 4. ECG changes associated with prior myocardial
infarction
Any Q wave in leads V2V3 0.02 sec or QS complex in leads V2
andV3.
Q wave 0.03 sec and 0.1 mV deep or QS complex in leads I, II,
aVL, aVF or V4V6 in any two leads of a contiguous lead
grouping (I,aVL; VV6;II,III,aVF).a
R wave 0.04 sec in V1V2 and R/S 1 with a concordant
positive T wave in absence of conduction defect.
a The same criteria are used for supplemental leads V7V9.
Table 5. Common ECG pitfalls in diagnosing myocardial
infarction
False positives
d Early repolarization
d LBBB
d Pre-excitation
d J point elevation syndromes, e.g. Brugada syndrome
d Peri-/myocarditis
d Pulmonary embolism
d Subarachnoid haemorrhage
d Metabolic disturbances such as hyperkalaemia
d Cardiomyopathy
d Lead transposition
d Cholecystitis
d Persistent juvenile pattern
d Malposition of precordial ECG electrodes
d Tricyclic antidepressants or phenothiazines
False negatives
d Prior MI with Q-waves and/or persistent ST elevation
d Right ventricular pacing
d LBBB
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likelihood of MI is increased; for example, minor Q
waves >0.02 sec and <0.03 sec that are  0.1 mV
deep are suggestive of prior MI if accompanied by
inverted T waves in the same lead group. Other
validated MI coding algorithms, such as the Minne-
sota Code and WHO MONICA, have been used
in epidemiological studies and clinical trials [3].
S I L E N T MYOCARD I A L I N F A R C T I ON
Asymptomatic patients who develop new pathologic
Q wave criteria for MI detected during routine
ECG follow-up, or reveal evidence of MI by cardiac
imaging, that cannot be directly attributed to a coro-
nary revascularization procedure, should be termed
‘silent MI’ [4851]. In studies, silent Q wave MI
accounted for 9 e 37% of all non-fatal MI events
and were associated with a signiﬁcantly increased
mortality risk [48,49]. Improper lead placement or
QRS confounders may result in what appear to be
new Q waves or QS complexes, as compared to
a prior tracing. Thus, the diagnosis of a new silent
Q wave MI should be conﬁrmed by a repeat
ECG with correct lead placement, or by an imaging
study, and by focused questioning about potential
interim ischaemic symptoms.
COND I T I ON S THA T CON FOUND TH E
E CG D I AGNOS I S O F MYOCARD I A L
I N FA R C T I ON
A QS complex in lead V1 is normal. A Q wave
<0.03 sec and <25% of the R wave amplitude in
lead III is normal if the frontal QRS axis is between
-30 and 0. A Q wave may also be normal in aVL if
the frontal QRS axis is between 60 and 90. Septal
Q waves are small, non-pathological Q waves <0.03
sec and <25% of the R-wave amplitude in leads I,
aVL, aVF, and V4V6. Pre-excitation, obstructive,
dilated or stress cardiomyopathy, cardiacamyloidosis, LBBB, left anterior hemiblock, LVH,
right ventricular hypertrophy, myocarditis, acute cor
pulmonale, or hyperkalaemia may be associated
with Q waves or QS complexes in the absence of
MI. ECG abnormalities that mimic myocardial
ischaemia or MI are presented in Table 5.
I M AG I NG T E CHN I QU E S
Non-invasive imaging plays many roles in patients
with known or suspected MI, but this section
concerns only its role in the diagnosis and character-
isation of MI. The underlying rationale is that
regional myocardial hypoperfusion and ischaemia
lead to a cascade of events, including myocardial
dysfunction, cell death and healing by ﬁbrosis.
Important imaging parameters are therefore perfu-
sion, myocyte viability, myocardial thickness, thick-
ening and motion, and the effects of ﬁbrosis on the
kinetics of paramagnetic or radio- opaque contrast
agents.
Commonly used imaging techniques in acute
and chronic infarction are echocardiography, radio-
nuclide ventriculography, myocardial perfusion
scintigraphy (MPS) using single photon emission
computed tomography (SPECT), and magnetic
resonance imaging (MRI). Positron emission
tomography (PET) and X-ray computed tomog-
raphy (CT) are less common [52]. There is consid-
erable overlap in their capabilities and each of the
techniques can, to a greater or lesser extent, assess
Table 6. Tabulation in clinical trials of MI types according to multiples of the 99th percentile upper reference limit of the applied
cardiac biomarker
MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; CABG ¼ coronary artery bypass grafting.
a Biomarker values are unavailable because of death before blood samples are obtained (blue area). Red areas indicate arbitrarily deﬁned cTn values below the MI
decision limit whether PCI or CABG.
b Restenosis is deﬁned as 50% stenosis at coronary angiography or a complex lesion associated with a rise and/or fall of cTn values >99th percentile URL and no
other signiﬁcant obstructive CAD of greater severity following: (i) initially successful stent deployment or (ii) dilatation of a coronary artery stenosis with balloon
angioplasty (<50%).
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the radionuclide techniques provide a direct assess-
ment of myocyte viability, because of the inherent
properties of the tracers used. Other techniques
provide indirect assessments of myocardial viability,
such as contractile response to dobutamine by echo-
cardiography or myocardial ﬁbrosis by MR.
Echocardiography. The strength of echocardiog-
raphy is the assessment of cardiac structure and func-
tion, in particular myocardial thickness, thickening
and motion. Echocardiographic contrast agents can
improve visualisation of the endocardial border and
can be used to assess myocardial perfusion and
microvascular obstruction. Tissue Doppler and strain
imaging permit quantiﬁcation of global and regional
function [53]. Intravascular echocardiographic
contrast agents have been developed that target
speciﬁc molecular processes, but these techniques
have not yet been applied in the setting of MI [54].
Radionuclide imaging. Several radionuclide tracers
allow viable myocytes to be imaged directly,
including the SPECT tracers thallium-201, techne-
tium-99m MIBI and tetrofosmin, and the PET
tracers F-2-ﬂuorodeoxyglucose (FDG) and
rubidium-82 [18,52]. The strength of the SPECT
techniques is that these are the only commonly
available direct methods of assessing viability,
although the relatively low resolution of the images
leaves them at a disadvantage for detecting small
areas of MI. The common SPECT radiopharma-
ceuticals are also tracers of myocardial perfusion
and the techniques thereby readily detect areas of
MI and inducible perfusion abnormalities. ECG-
gated imaging provides a reliable assessment of
myocardial motion, thickening and global function.
Evolving radionuclide techniques that are relevant
to the assessment of MI include imaging ofsympathetic innervation using iodine-123-labelled
meta-iodo-benzylguanidine (mIBG), [55] imaging
of matrix metalloproteinase activation in ventricular
remodelling, [56,57] and reﬁned assessment of
myocardial metabolism [58].
Magnetic resonance imaging. The high tissue
contrast of cardiovascular MRI provides an accurate
assessment of myocardial function and it has similar
capability to echocardiography in suspected acute
MI. Paramagnetic contrast agents can be used to
assess myocardial perfusion and the increase in extra-
cellular space that is associated with the ﬁbrosis of
prior MI. These techniques have been used in
the setting of acute MI, [59,60] and imaging of
myocardial ﬁbrosis by delayed contrast enhancement
is able to detect even small areas of subendocardial
MI. It is also of value in detecting myocardial disease
states that can mimic MI, such as myocarditis [61].
Computed tomography. Infarcted myocardium is
initially visible as a focal area of decreased left
ventricle (LV) enhancement, but later imaging
shows hyper- enhancement, as with late gadolinium
imaging by MRI [62]. This ﬁnding is clinically rele-
vant because contrast-enhanced CT may be per-
formed for suspected pulmonary embolism and
aortic dissectiondconditions with clinical features
that overlap with those of acute MIdbut the tech-
nique is not used routinely. Similarly, CT assess-
ment of myocardial perfusion is technically feasible
but not yet fully validated.
Applying imaging in acute myocardial infarction.
Imaging techniques can be useful in the diagnosis of
acute MI because of their ability to detect wall motion
abnormalities or loss of viable myocardium in the pres-
ence of elevated cardiac bio- marker values. If, for
some reason, biomarkers have not been measured or
may have normalized, demonstration of new loss of
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causes meets the criteria for MI. Normal function
and viability have a very high negative predictive value
and practically exclude acute MI [63]. Thus, imaging
techniques are useful for early triage and discharge of
patients with suspected MI. However, if biomarkers
have been measured at appropriate times and are
normal, this excludes an acute MI and takes prece-
dence over the imaging criteria.
Abnormal regional myocardial motion and
thickening may be caused by acute MI or by one
or more of several other conditions, including prior
MI, acute ischaemia, stunning or hibernation. Non-
ischaemic conditions, such as cardiomyopathy and
inﬂammatory or inﬁltrative diseases, can also lead
to regional loss of viable myocardium or functional
abnormality. Therefore, the positive predictive value
of imaging for acute MI is not high unless these
conditions can be excluded, and unless a new abnor-
mality is detected or can be presumed to have arisen
in the setting of other features of acute MI.
Echocardiography provides an assessment of
many non- ischaemic causes of acute chest pain,
such as peri-myocarditis, valvular heart disease,
cardiomyopathy, pulmonary embolism or aortic
dissection [53]. It is the imaging technique of
choice for detecting complications of acute MI,
including myocardial free wall rupture, acute
ventricular septal defect, and mitral regurgitation
secondary to papillary muscle rupture or ischaemia.
Radionuclide imaging can be used to assess the
amount of myocardium that is salvaged by acute
revascularization [64]. Tracer is injected at the
time of presentation, with imaging deferred until
after revascularization, providing a measure of
myocardium at risk. Before discharge, a second
resting injection provides a measure of ﬁnal infarct
size, and the difference between the two corre-
sponds to the myocardium that has been salvaged.
Applying imaging in late presentation of myocar-
dial infarction. In case of late presentation after sus-
pected MI, the presence of regional wall motion
abnormality, thinning or scar in the absence of
non-ischaemic causes, provides evidence of past
MI. The high resolution and speciﬁcity of late
gadolinium enhancement MRI for the detection
of myocardial ﬁbrosis has made this a very valuable
technique. In particular, the ability to distinguish
between subendocar- dial and other patterns of
ﬁbrosis provides a differentiation between ischaemic
heart disease and other myocardial abnormalities.
Imaging techniques are also useful for risk stratiﬁca-
tion after a deﬁnitive diagnosis of MI. Thedetection of residual or remote ischaemia and/or
ventricular dysfunction provides powerful indicators
of later outcome.
D I AGNO S T I C C R I T E R I A FOR
MYOCARD I A L I N F A R C T I ON W I TH P C I
(M I T Y P E 4 )
Balloon inﬂation during PCI often causes transient
ischaemia, whether or not it is accompanied by chest
pain or STeT changes. Myocardial injury with
necrosis may result from recognizable peri- proce-
dural eventsdalone or in combinationdsuch as
coronary dissection, occlusion of a major coronary
artery or a side-branch, disruption of collateral ﬂow,
slow ﬂow or no-reﬂow, distal embolization, and
microvascular plugging. Embolization of intracoro-
nary thrombus or atherosclerotic particulate debris
may not be preventable, despite current anticoagulant
and antiplatelet adjunctive therapy, aspiration or
protection devices. Such events induce inﬂammation
of the myocardium surrounding islets of myocardial
necrosis [65]. New areas of myocardial necrosis
have been demonstrated by MRI following PCI [66].
The occurrence of procedure-related myocardial
cell injury with necrosis can be detected by measure-
ment of cardiac biomarkers before the procedure,
repeated 3e6 h later and, optionally, further re-
measurement 12 h thereafter. Increasing levels can
only be interpreted as procedure-related myocardial
injury if the pre-procedural cTn value is normal
(99th percentile URL) or if levels are stable or
falling [67,68]. In patients with normal pre- proce-
dural values, elevation of cardiac biomarker values
above the 99th percentile URL following PCI are
indicative of procedure-related myocardial injury.
In earlier studies, increased values of post-proce-
dural cardiac biomarkers, especially CKMB, were
associated with impaired outcome [69,70].
However, when cTn concentrations are normal
before PCI and become abnormal after the proce-
dure, the threshold above the 99th percentile
URLdwhereby an adverse prognosis is evidentdis
not well deﬁned [71] and it is debatable whether
such a threshold even exists [72]. If a single baseline
cTn value is elevated, it is impossible to determine
whether further increases are due to the procedure
or to the initial process causing the elevation. In
this situation, it appears that the prognosis is largely
determined by the pre- procedural cTn level [71].
These relationships will probably become even
more complex for the new high-sensitivity troponin
assays [70].
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percentile URL) baseline cTn concentrations, eleva-
tions of cTn >5  99th percentile URL occurring
within 48 h of the proceduredplus either (i)
evidence of prolonged ischaemia (20 min) as
demonstrated by prolonged chest pain, or (ii)
ischaemic ST changes or new pathological Q waves,
or (iii) angiographic evidence of a ﬂow limiting
complication, such as of loss of patency of a side
branch, persistent slow-ﬂow or no-reﬂow, emboli-
zation, or (iv) imaging evidence of new loss of viable
myocardium or new regional wall motion
abnormalitydis deﬁned as PCI-related MI (type
4a). This threshold of cTn values >5  99th percen-
tile URL is arbitrarily chosen, based on clinical
judgement and societal implications of the label of
peri-procedural MI. When a cTn value is 5 
99th percentile URL after PCI and the cTn value
was normal before the PCIdor when the cTn value
is >5  99th percentile URL in the absence of
ischaemic, angiographic or imaging ﬁndingsdthe
term ‘myocardial injury’ should be used.
If the baseline cTn values are elevated and are
stable or falling, then a rise of >20% is required
for the diagnosis of a type 4a MI, as with reinfarc-
tion. Recent data suggest that, when PCI is delayed
after MI until biomarker concentrations are falling
or have normalized, and elevation of cardiac
biomarker values then reoccurs, this may have
some long-term signiﬁcance. However, additional
data are needed to conﬁrm this ﬁnding [73].
A subcategory of PCI-related MI is stent throm-
bosis, as documented by angiography and/or at autopsy
and a rise and/or fall of cTn values >99th percentile
URL (identiﬁed as MI type 4b). In order to stratify
the occurrence of stent thrombosis in relation to the
timing of the PCI procedure, the Academic Research
Consortium recommends temporal categories of ‘early’
(0 to 30 days), ‘late’ (31 days to 1 year), and ‘very late’
(>1 year) to distinguish likely differences in the contri-
bution of the various pathophysio- logical processes
during each of these intervals [74]. Occasionally, MI
occurs in the clinical setting ofwhat appears to be a stent
thrombosis: however, at angiography, restenosis is
observed without evidence of thrombus (see section
on clinical trials).
D I AGNOS T I C C R I T E R I A FOR
MYOCARD I A L I N F A R C T I ON W I TH CABG
(M I T Y P E 5 )
During CABG, numerous factors can lead to peri-
procedural myocardial injury with necrosis. Theseinclude direct myocardial trauma from (i) suture
placement or manipulation of the heart, (ii) coro-
nary dissection, (iii) global or regional ischaemia
related to inadequate intra-operative cardiac protec-
tion, (iv) microvascular events related to reperfusion,
(v) myocardial injury induced by oxygen free radical
generation, or (vi) failure to reperfuse areas of the
myocardium that are not subtended by graftable
vessels [7577]. MRI studies suggest that most
necrosis in this setting is not focal but diffuse and
localized in the subendocardium [78].
In patients with normal values before surgery,
any increase of cardiac biomarker values after
CABG indicates myocardial necrosis, implying
that an increasing magnitude of biomarker concen-
trations is likely to be related to an impaired
outcome. This has been demonstrated in clinical
studies employing CKMB, where elevations 5, 10
and 20 times the URL after CABG were associated
with worsened prognosis; similarly, impaired
outcome has been reported when cTn values were
elevated to the highest quartile or quintile of the
measurements [7983].
Unlike prognosis, scant literature exists con-
cerning the use of biomarkers for deﬁning an MI
related to a primary vascular event in a graft or
native vessel in the setting of CABG. In addition,
when the baseline cTn value is elevated (>99th
percentile URL), higher levels of biomarker values
are seen post-CABG. Therefore, bio- markers
cannot stand alone in diagnosing MI in this
setting. In view of the adverse impact on survival
observed in patients with signiﬁcant elevation of
biomarker concentrations, this Task Force
suggests, by arbitrary convention, that cTn values
>10  99th percentile URL during the ﬁrst 48 h
following CABG, occurring from a normal base-
line cTn value (99th percentile URL). In addi-
tion, either (i) new pathological Q waves or new
LBBB, or (ii) angiogra- phically documented new
graft or new native coronary artery occlusion, or
(iii) imaging evidence of new loss of viable myocar-
dium or new regional wall motion abnormality,
should be considered as diagnostic of a CABG-
related MI (type 5). Cardiac biomarker release is
considerably higher after valve replacement with
CABG than with bypass surgery alone, and with
on-pump CABG compared to off-pump CABG
[84]. The threshold described above is more robust
for isolated on-pump CABG. As for PCI, the
existing principles from the universal deﬁnition of
MI should be applied for the deﬁnition of MI
>48 h after surgery.
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UNDE RGO I NG OTH E R CARD I A C
P ROC EDUR E S
New STeT abnormalities are common in patients
who undergo cardiac surgery. When new patholog-
ical Q waves appear in different territories than
those identiﬁed before surgery, MI (types 1 or 2)
should be considered, particularly if associated
with elevated cardiac biomarker values, new wall
motion abnormalities or haemodynamic instability.
Novel procedures such as transcatheter aortic
valve implantation (TAVI) or mitral clip may cause
myocardial injury with necrosis, both by direct
trauma to the myocardium and by creating regional
ischaemia from coronary obstruction or emboliza-
tion. It is likely that, similarly to CABG, the
more marked the elevation of the biomarker values,
the worse the prognosisdbut data on that are not
available.
Modiﬁed criteria have been proposed for the
diagnosis of peri- procedural MI 72 h after aortic
valve implantation [85]. However, given that there
is too little evidence, it appears reasonable to apply
the same criteria for procedure-related MI as stated
above for CABG.
Ablation of arrhythmias involves controlled
myocardial injury with necrosis, by application of
warming or cooling of the tissue.
The extent of the injury with necrosis can be
assessed by cTn measurement: however, an eleva-
tion of cTn values in this context should not be
labelled as MI.MYOCARD I A L I N F A R C T I ON
A S SOC I A T E D W I TH NON - CA RD I A C
P ROC EDUR E S
Perioperative MI is the most common major perio-
perative vascular complication in major non-cardiac
surgery, and is associated with a poor prognosis
[86,87]. Most patients who have a perioperative
MI will not experience ischaemic symptoms. Never-
theless, asymptomatic perioperative MI is as
strongly associated with 30-day mortality, as is
symptomatic MI [86]. Routine monitoring of
cardiac biomarkers in high-risk patients, both prior
to and 48e72 h after major surgery, is therefore rec-
ommended. Measurement of high- sensitivity cTn
in post-operative samples reveals that 45% of
patients have levels above the 99th percentile URL
and 22% have an elevation and a rising pattern of
values indicative of evolving myocardial necrosis[88]. Studies of patients undergoing major non-
cardiac surgery strongly support the idea that many
of the infarctions diagnosed in this context are
caused by a prolonged imbalance between myocar-
dial oxygen supply and demand, against a back-
ground of CAD [89,90]. Together with a rise and/
or fall of cTn values, this indicates MI type 2.
However, one pathological study of fatal periopera-
tive MI patients showed plaque rupture and platelet
aggregation, leading to thrombus formation, in
approximately half of such events; [91] that is to
say, MI type 1. Given the differences that probably
exist in the therapeutic approaches to each, close
clinical scrutiny and judgement is needed.
MYOCARD I A L I N FA R C T I ON I N TH E
I N T EN S I V E CAR E UN I T
Elevations of cTn values are common in patients in
the intensive care unit and are associated with adverse
prognosis, regardless of the underlying disease state
[92,93]. Some elevations may reﬂect MI type 2 due
to underlying CAD and increased myocardial oxygen
demand [94]. Other patients may have elevated
values of cardiac biomarkers, due to myocardial injury
with necrosis induced by catecholamine or direct
toxic effect from circulating toxins. Moreover, in
some patients, MI type 1 may occur. It is often a chal-
lenge for the clinician, caring for a critically ill patient
with severe single organ or multi-organ pathology, to
decide on a plan of action when the patient has
elevated cTn values. If and when the patient recovers
from the critical illness, clinical judgement should be
employed to decide whetherdand to what extentd
further evaluation for CAD or structural heart
disease is indicated [95].
R E CURR EN T MYOCARD I A L
I N F A R C T I ON
‘Incident MI’ is deﬁned as the individual’s ﬁrst MI.
When features of MI occur in the ﬁrst 28 days after
an incident event, this is not counted as a new event
for epidemiological purposes. If characteristics of
MI occur after 28 days following an incident MI,
it is considered to be a recurrent MI [3].
R E I N F A R C T I ON
The term ‘reinfarction’ is used for an acute MI that
occurs within 28 days of an incident- or recurrent
MI [3]. The ECG diagnosis of suspected reinfarc-
tion following the initial MI may be confounded
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289by the initial evolutionary ECG changes. Reinfarc-
tion should be considered when ST elevation 0.1
mV recurs, or new pathognomonic Q waves appear,
in at least two contiguous leads, particularly when
associated with ischaemic symptoms for 20 min or
longer. Re-elevation of the ST-segment can,
however, also be seen in threatened myocardial
rupture and should lead to additional diagnostic
workup. ST depression or LBBB alone are non-
speciﬁc ﬁndings and should not be used to diagnose
reinfarction.
In patients in whom reinfarction is suspected
from clinical signs or symptoms following the initial
MI, an immediate measurement of cTn is recom-
mended. A second sample should be obtained
3e6 h later. If the cTn concentration is elevated,
but stable or decreasing at the time of suspected
reinfarction, the diagnosis of reinfarction requires
a 20% or greater increase of the cTn value in the
second sample. If the initial cTn concentration is
normal, the criteria for new acute MI apply.MYOCARD I A L I N J U R Y OR I N FA R C T I ON
A S SOC I A T ED W I TH HEA R T FA I L U R E
Depending on the assay used, detectable-to-clearly
elevated cTn values, indicative of myocardial injury
with necrosis, may be seen in patients with HF
syndrome [96]. Using high-sensitivity cTn assays,
measurable cTn concentrations may be present in
nearly all patients with HF, with a signiﬁcant
percentage exceeding the 99th percentile URL,
particularly in those with more severe HF syndrome,
such as in acutely decompensated HF [97].
Whilst MI type 1 is an important cause of
acutely decompen-sated HFdand should always
be considered in the context of an acute presenta-
tiondelevated cTn values alone, in a patient with
HF syndrome, do not establish the diagnosis of
MI type 1 and may, indeed, be seen in those with
non-ischaemic HF. Beyond MI type 1, multiple
mechanisms have been invoked to explain measur-
able-to-pathologically elevated cTn concentrations
in patients with HF [96,97]. For example, MI
type 2 may result from increased transmural pres-
sure, small-vessel coronary obstruction, endothelial
dysfunction, anaemia or hypotension. Besides MI
type 1 or 2, cardiomyocyte apoptosis and autophagy
due to wall stretch has been experimentally demon-
strated. Direct cellular toxicity related to inﬂamma-
tion, circulating neurohormones, inﬁltrative
processes, as well as myocarditis and stresscardiomyopathy, may present with HF and
abnormal cTn measurement [97].
Whilst prevalent and complicating the diagnosis
of MI, the presence, magnitude and persistence of
cTn elevation in HF is increasingly accepted to be
an independent predictor of adverse outcomes in
both acute and chronic HF syndrome, irrespective
of mechanism, and should not be discarded as ‘false
positive’ [97,98].
In the context of an acutely decompensated HF
presentation, cTn I or T should always be promptly
measured and ECG recorded, with the goal of iden-
tifying or excluding MI type 1 as the precipitant. In
this setting, elevated cTn values should be inter-
preted with a high level of suspicion for MI type
1 if a signiﬁcant rise and/or fall of the marker are
seen, or if it is accompanied by ischaemic symp-
toms, new ischaemic ECG changes or loss of
myocardial function on non-invasive testing. Coro-
nary artery anatomy may often be well-known; such
knowledge may be used to interpret abnormal
troponin results. If normal coronary arteries are
present, either a type 2 MI or a non-coronary mech-
anism for troponin release may be invoked [97].
On the other hand, when coronary anatomy is
not established, the recognition of a cTn value in
excess of the 99th percentile URL alone is not sufﬁ-
cient to make a diagnosis of acute MI due to CAD,
nor is it able to identify the mechanism for the
abnormal cTn value. In this setting, further infor-
mation, such as myocardial perfusion studies, coro-
nary angiography, or MRI is often required to better
understand the cause of the abnormal cTn measure-
ment. However, it may be difﬁcult to establish the
reason for cTn abnormalities, even after such inves-
tigations [96,97].
AP P L I C A T I ON O F M I I N C L I N I C A L
T R I A L S AND QUA L I T Y A S SURANC E
P ROGRAMMES
In clinical trials, MI may be an entry criterion or an
end-point. A universal deﬁnition for MI is of great
beneﬁt for clinical studies, since it will allow a stan-
dardized approach for interpretation and comparison
across different trials. The deﬁnition of MI as an
entry criterion, e.g. MI type 1 and not MI type 2,
will determine patient characteristics in the trial.
Occasionally MI occurs and, at angiography, resteno-
sis is the only angiographic explanation [99,100].
This PCI-related MI type might be designated as
an ‘MI type 4c’, deﬁned as50% stenosis at coronary
angiography or a complex lesion associated with a rise
Thygesen et al. G L O B A L H E A R T , V O L . 7 , N O . 4 , 2 0 1 2
Third Universal Deﬁnition of Myocardial Infarction
D e c e m b e r 2 0 1 2 : 2 7 5 – 2 9 5
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no other signiﬁcant obstructive CAD of greater
severity following: (i) initially successful stent deploy-
ment or (ii) dilatation of a coronary artery stenosis
with balloon angioplasty (< 50%).
In recent investigations, different MI deﬁnitions
have been employed as trial outcomes, thereby
hampering comparison and generalization between
these trials. Consistency among investigators and
regulatory authorities, with regard to the deﬁnition
of MI used as an endpoint in clinical investigations,
is of substantial value. Adaptation of the deﬁnition
to an individual clinical study may be appropriate
in some circumstances and should have a wellarticu-
lated rationale. No matter what, investigators should
ensure that a trial provides comprehensive data for
the various types of MI and includes the 99th
percentile URL decision limits of cTn or other
biomarkers employed. Multiples of the 99th percen-
tiles URL may be indicated as shown in Table 6.
This will facilitate comparison of trials and meta-
analyses.
Because different assays may be used, including
newer, highersensitivity cTn assays in large multi-
centre clinical trials, it is advisable to consistently
apply the 99th percentile URL. This will not totally
harmonize troponin values across different assays,
but will improve the consistency of the results. In
patients undergoing cardiac procedures, the inci-
dence of MI may be used as a measure of quality,
provided that a consistent deﬁnition is applied by
all centres participating in the quality assurance pro-
gramme. To be effective and to avoid bias, this type
of assessment will need to develop a paradigm to
harmonize the different cTn assay results across
sites.
PUB L I C PO L I C Y IMP L I C A T I ON S O F TH E
AD JU S TMENT O F TH E M I D E F I N I T I ON
Revision of the deﬁnition of MI has a number of
implications for individuals as well as for society at
large. A tentative or ﬁnal diagnosis is the basis for
advice about further diagnostic testing, lifestyle
changes, treatment and prognosis for the patient.
The aggregate of patients with a particular diagnosis
is the basis for health care planning and policy and
resource allocation.
One of the goals of good clinical practice is to
reach a deﬁnitive and speciﬁc diagnosis, which is
supported by current scientiﬁc knowledge. The
approach to the deﬁnition of MI outlined in this
document meets this goal. In general, theconceptual meaning of the term ‘myocardial infarc-
tion’ has not changed, although new, sensitive diag-
nostic methods have been developed to diagnose
this entity. Thus, the diagnosis of acute MI is a clin-
ical diagnosis based on patient symptoms, ECG
changes, and highly sensitive biochemical markers,
as well as information gleaned from various imaging
techniques. It is important to characterize the type
of MI as well as the extent of the infarct, residual
LV function, and the severity of CAD and other
risk factors, rather than merely making a diagnosis
of MI. The information conveyed about the
patient’s prognosis and ability to work requires
more than just the mere statement that the patient
has suffered an MI. The many additional factors
just mentioned are also required so that appropriate
social, family, and employment decisions can be
made. A number of risk scores have been developed
to predict the prognosis after MI. The classiﬁcation
of the various other prognostic entities associated
with MI should lead to a reconsideration of the clin-
ical coding entities currently employed for patients
with the myriad conditions that can lead to myocar-
dial necrosis, with consequent elevation of
biomarker values.
It should be appreciated that the current modiﬁ-
cation of the deﬁnition of MI may be associated
with consequences for the patients and their families
in respect of psychological status, life insurance,
professional career, as well as driving- and pilots’
licences. The diagnosis is associated also with soci-
etal implications as to diagnosis-related coding,
hospital reimbursement, public health statistics,
sick leave, and disability attestation. In order to
meet this challenge, physicians must be adequately
informed of the altered diagnostic criteria. Educa-
tional materials will need to be created and treat-
ment guidelines must be appropriately adapted.
Professional societies and healthcare planners
should take steps to facilitate the rapid dissemina-
tion of the revised deﬁnition to physicians, other
health care professionals, administrators, and the
general public.
GLOBA L P E R S P E C T I V E S O F TH E
D E F I N I T I ON O F MYOCARD I A L
I N F A R C T I ON
Cardiovascular disease is a global health problem.
Understanding the burden and effects of CAD in
populations is of critical importance. Changing clin-
ical deﬁnitions, criteria and biomarkers add chal-
lenges to our understanding and ability to improve
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291the health of the public. The deﬁnition of MI for
clinicians has important and immediate therapeutic
implications. For epidemiologists, the data are
usually retrospective, so consistent case deﬁnitions
are critical for comparisons and trend analysis.
The standards described in this report are suitable
for epidemiology studies. However, to analyse
trends over time, it is important to have consistent
deﬁnitions and to quantify adjustments when
biomarkers or other diagnostic criteria change
[101]. For example, the advent of cTn dramatically
increased the number of diagnosable MIs for epide-
miologists [3,102].
In countries with limited economic resources,
cardiac biomarkers and imaging techniques may
not be available except in a few centres, and even
the option of ECG recordings may be lacking. In
these surroundings, the WHO states that biomarker
tests or other high-cost diagnostic testing are unﬁt
for use as compulsory diagnostic criteria [3]. The
WHO recommends the use of the ESC/ACCF/
AHA/WHF Universal MI Deﬁnition in settings
without resource constraints, but recommends
more ﬂexible standards in resource-constrained
locations [3].
Cultural, ﬁnancial, structural and organisational
problems in the different countries of the world in
the diagnosis and therapy of acute MI will require
ongoing investigation. It is essential that the gap
between therapeutic and diagnostic advances beaddressed in this expanding area of cardiovascular
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